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Abstract
Background—Heterogeneity of muscle-invasive bladder cancer (MIBC) has been characterized 
using whole genome mRNA expression data, showing distinct molecular and clinicopathological 
characteristics by subtypes. However, associations between risk factors and molecular subtypes 
have not been reported.
Methods—Four previously published schemes were used to categorize molecular subtypes in 
372 MIBC patients from the Cancer Genome Atlas (TCGA). Data on gene expression (RNA-seq), 
demographic, and clinicopathological characteristics were retrieved through TCGA data portal. 
Polytomous logistic regression was used to estimate the associations of subtypes by different 
schema with age at diagnosis, obesity, and smoking.
Results—While some quantitative variation was evident, distinct molecular subtype schemes 
showed considerable consistency in the association with the risk factors. Generally, compared to 
patients with luminal-like tumors, patients with basal-like subtypes were more likely to be older 
(OR75+yrs vs. <60 yrs range=1.32–2.89), obese (ORobese vs. normal range=1.30–3.05), and to start 
smoking at early age (OR<18 yrs vs. 25+ yrs range=1.11–4.57).
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Conclusions—Different molecular subtypes of MIBC may have distinct risk profiles. Large 
population-based studies with detailed information on bladder cancer risk factors are needed to 
further define etiologic heterogeneity for bladder cancer.
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Background
Recently, molecular heterogeneity of muscle-invasive bladder cancer (MIBC) has been 
characterized using whole genome mRNA expression data (1–4). There are two to five 
molecular subtypes reported by different investigators: at Lund University (Lund: urothelial-
like A, genomically unstable, infiltrated, urothelial-like B, and squamous cell carcinoma-
like), MD Anderson (MDA: basal, luminal, and p53-like), the Cancer Genome Atlas 
(TCGA: Cluster I-IV), and our institution (UNC: basal and luminal) (1–5). These molecular 
schemes have considerable similarities (e.g. the existence of basal/squamous-like subtype), 
and all schemes show some value in predicting progression (6). However, the etiologic 
relevance of the molecular subtypes is unknown.
We hypothesized that different mechanistic pathways are involved in the development and 
progression of different MIBC subtypes, and therefore, that these subtypes may differ in 
associations with risk factors. To test this hypothesis, we classified 372 MIBCs from TCGA 
data using the four published subtyping schemes (Lund, MDA, TCGA, and UNC), and then 
evaluated the subtype-specific associations of each scheme with age at diagnosis, obesity, 
and cigarette smoking.
Methods
The study population included 372 MIBCs patients from TCGA with available molecular 
subtype data by UNC-BASE47 (4). Data on gene expression (RNA-seq), demographic, and 
clinicopathological characteristics were retrieved through TCGA data portal (https://tcga-
data.nci.nih.gov/tcga/). MDA and Lund subtype calls were directly extracted from the results 
of previous published literatures (1–3, 5). TCGA subtypes of 129 MIBCs were extracted 
from the original published paper (2). The rest 241 cases were classified using the ClaNC 
method with the nearest centroid classifier estimated based on the silhouette width for the 
129 cases and the 2,708 genes in the original paper (7, 8). All of the patients had provided 
informed consent to TCGA. Protocols were reviewed by the Institutional Review Board at 
all participating institutions.
Information of demographic, anthropometric, and clinicopathologic characteristics in TCGA 
data base was extracted from clinical records (https://tcga-data.nci.nih.gov/tcga/; file name: 
nationwidechildrens.org_clinical_patient_blca). Weight and height were used to calculate 
body mass index (BMI). In the analyses, age at diagnosis and BMI were used both 
continuously and categorically (age, <60 years, 60–<75 years, or ≥ 75 years; BMI, normal 
weight as <25kg/m2, overweight as 25-<30kg/m2, or obese as ≥30kg/m2). Never smokers 
were defined as patients who were not smoking at the time of interview and had smoked less 
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than 100 cigarettes in their lifetime. Former smokers were defined as patients who were not 
smoking at the time of interview but had smoked at least 100 cigarettes in their lifetime. 
Current smokers were defined as patients who were daily or occasionally smoking at the 
time of interview. Ever smokers (former and current smokers) were asked about their 
smoking history, including age at smoking initiation, and the beginning and end of smoking 
period along with the frequency and intensity of smoking. Smoking variables in this study 
were defined as smoking status (never, former, or current), age at smoking initiation (<18 
years, 18-<25 years, or ≥25 years), total smoking years (<17 years, 17-<40 years, or ≥ 40 
years), total pack-years (<20 years, 20–40 years, or ≥ 40 years) among ever smokers, and 
quitting recency (time since quitting <10 years or ≥ 10 years) among former smokers.
The differences in variable distribution were assessed using ANOVA F-tests for continuous 
variables, and χ2 test or Fisher’s exact test for categorical variables. Polytomous logistic 
regression was used to calculate unadjusted odds ratios (ORs), adjusted ORs, and the 
corresponding 95% confidence intervals (CIs). Overall association heterogeneity was 
estimated by Wald χ2 test (9). To account for potential confounders, associations with 
obesity and smoking were adjusted for age. Associations with obesity were additionally 
adjusted for smoking status. Associations with age at smoking initiation were additionally 
adjusted for total smoking years and pack-years, given previously reported correlation 
between these variables (10, 11) and the observation that smoking initiation was associated 
with both variables in TCGA (total smoking years, χ2 test p=0.04; pack-years, χ2 test p 
<0.01). All statistical tests were two-sided with α of 0.05. All analyses were performed 
using SAS version 9.2 (SAS Institute).
Results
Molecular subtypes by different schemes
To facilitate the comparison across different schemes, we used the simplest two-subtype 
UNC scheme (UNC luminal vs UNC basal) as the primary scheme. Its distribution by 
clinicopathological features and subtypes defined by other schemes is shown in 
Supplementary Table 1. Consistent with previous analyses, UNC luminal subtype was 
associated with low-grade and early-stage papillary tumors (p<0.01). Subtypes defined by 
the other schemes showed considerable overlap (Figure 1 and Supplementary Table 1). The 
majority of UNC luminal tumors were classified as Lund urothelial-like A/genomically 
unstable (91%), MDA luminal (75%), and TCGA Cluster I (64%), while the majority of 
UNC basal tumors were classified as Lund infiltrated/urothelial-like B/SCC-like (91%), and 
MDA basal (79%). Almost all of squamous-like tumors (TCGA Cluster III, 98%; Lund 
SCC-like, 100%) were classified as UNC basal. 89% of TCGA Cluster IV, which has been 
hypothesized to correspond to claudin-low subtype (12, 13) were classified as UNC basal. 
MDA p53-like did not show a significant correlation with UNC subtypes, with an almost 
even distribution of UNC basal and luminal subtypes in our analysis (χ2 test p=0.41). This is 
an interesting observation because this subtype was previously proposed as a subset of UNC 
luminal (1, 12).
Considering the overlap and similarity across different schemes, for simplicity and to ensure 
statistical power in the following analyses we named UNC luminal, TCGA Cluster I&II, 
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MDA luminal, and Lund urothelial-like A/genomically unstable as “luminal-like” tumors; 
and named UNC basal, TCGA Cluster III&IV, MDA basal, and Lund infiltrated/urothelial-
like B/SCC-like as “basal-like” tumors.
Associations with age at diagnosis, obesity, and smoking
Luminal-like and basal-like tumors had unique risk factor associations. Generally, older (≥60 
years) and overweight/obese patients were more likely to have basal-like tumors across all 
subtype schemes, although not all schemes showed statistically significant associations 
(Table 1). The associations with obesity were independent of age. The magnitude of the 
association of subtype with obesity was slightly stronger for MDA and Lund schemes. 
Additional adjustment for smoking status did not substantially change the measures of the 
obesity-subtype association, except to decrease precision (Supplementary Table 2). On a 
continuous age scale, only MDA p53-like showed a significant association with age, with 
the odds increasing 0.06 (OR=1.06, 95% CI=1.02–1.10) for each one-year increment in age.
The associations between subtypes and cigarette smoking are shown in Table 2. Compared 
with luminal-like cases, basal-like cases tended to be former smokers, but none of the 
associations were statistically significant. Among ever smokers, patients starting smoking at 
earlier ages were significantly more likely to have basal-like subtypes. These associations 
were independent of age, but varied slightly for different schema, with stronger associations 
observed in MDA and Lund schemes. To account for the potential confounding effect by 
total smoking years and pack-years, we estimated ORs additionally adjusted for the two 
variables (Supplementary Table 2), with no significant changes observed in the magnitude of 
ORs. None of the following variables: time since quitting, total smoking years and pack-
years showed significant associations with subtypes by different schemes (Supplementary 
Table 3), while former smokers quitting ≥ 10 years and smokers with pack-years ≥ 40 were 
suggested to have higher risk for basal-like tumors.
Discussion
In this study we mapped the molecular subtypes by different schemes on 372 MIBCs 
patients from TCGA, and linked molecular subtypes to three of the most important risk 
factors of bladder cancer. In line with previous biological studies (1, 6, 12) where biological 
and clinicopathological associations with molecular subtypes have been similar across 
different schemes, we observed consistent associations with etiologic exposures. In general, 
patients with basal-like subtypes were more likely to be obese, diagnosed at advanced age, 
and to start smoking at an early age. However, etiologic associations appeared slightly 
stronger with the subtypes defined by MDA and Lund schemes.
Currently, there are no data describing the associations of risk factors with MIBC 
transcriptional subtype, although differences by subtypes defined by clinicopathlogical 
features have been reported (14–18). Considering that basal-like tumors tend to be higher 
grade and stage than luminal-like tumors, our findings are in line with the previous studies, 
in which smokers, obese and older patients have been consistently found to have higher 
stage and grade (14–18). Although earlier age of smoking initiation is associated with higher 
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risk for bladder cancer, its influence on pathological features of bladder cancer has received 
less investigation (19).
Biologic and genomic data already suggest that bladder cancers may develop and progress 
through distinct pathways, and the current analysis highlights a plausible role of risk factor 
exposures in initiating or promoting these pathways. These findings can provide important 
novel clues with public health relevance. For instance, we found age at smoking initiation 
was the strongest factor that may drive MIBC heterogeneity, and associated with basal-like 
subtype. This result suggests exposure of smoking in an early “susceptible window” may 
play a role at the early phase of tumorigenesis of basal-like tumors. Although pathways 
specifically linking early smoking initiation remain understudied, this hypothesis is 
supported by the recent studies of temporal tumor heterogeneity in non-small cell lung 
cancer, where smoking-related genomic events represent many of very early mutations in 
tumors (20, 21).
The heterogeneity in the association of bladder cancer with risk factors also provides novel 
explanations for some unresolved findings in epidemiological studies. For instance, given 
the heterogeneous relationship of obesity and MIBC subtype, the variation in subtype 
composition of study populations could contribute to the observed inconsistent findings in 
the association between obesity and MIBC (22, 23). Furthermore, relatively strong 
association of basal-like subtype with advanced age and smoking provides another 
interpretation for the increasing smoking-associated risk of bladder cancer observed since 
1990s (24–27), as obesity epidemic and population aging in the past decades potentially 
increased proportion of basal-like tumors in bladder cancer cases, which artificially could 
shift up the association between smoking and bladder cancer as a whole.
In the past decade, genetic, genomic and epigenetic analyses provide ample evidence for 
enormous diversity in tumor molecular features, and based on these features some cancers 
have been classified into several molecular subtypes. Recent analysis revealed that many 
molecular alterations are shared by certain subtype across cancers arising from different 
origins (e.g. basal subtype in breast and bladder cancers), suggesting common oncogenic 
pathways and similarities in cell type origins (e.g. urothelial basal cells and breast basal 
cells) (4, 28). In risk factor analyses, common risk factors are also observed in similar 
subtypes of different cancers, such as obesity and basal subtype in breast cancer and bladder 
cancer. Interestingly in this study we found age is positively associated with basal-like 
MIBC, which is on the opposite direction of the association with basal breast cancer. This 
distinct effect of age on the two diseases is reflected by their difference in age distribution, 
where age distribution of breast cancer follows a bimodal pattern with different intrinsic 
subtype enriched in different age groups (29), while bladder cancer shows an unimodal 
pattern with highest rate observed among people aged 75–84 years (30). Likely these 
differences result from differences in tissue/organ of origin, etiology determined by 
exposome (a totality of exposure, e.g. hormone) and host characteristics. However, current 
data from both biological and epidemiological studies are still not enough to explain the 
similarities and differences in the subtype-specific etiology.
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Our analysis has some limitations. This study used TCGA data, which is not originally 
designed to study risk factors. Consequently, the completeness and accuracy of information 
on risk factors are lower than well-designed epidemiological studies or clinical trials. For 
instance, in our analysis the missing percentage of BMI was 13%, which may influence the 
association estimates quantitatively, although less likely substantially. Moreover, TCGA data 
includes a relatively low number of female, non-white cases, and non-muscle invasive cases. 
Therefore we cannot estimate the associations among these subpopulations, although 
associations of bladder subtype with invasive status, gender and race have been suggested (1, 
4, 31–33). At last, our study sample size is small, leading to imprecise effect estimates (e.g. 
ORs of MDA p53-like). However, our results suggest that further research to evaluate 
etiologic heterogeneity may reveal complexities in associations for established risk factors, 
and may help to identify novel risk factors and public health strategies for bladder cancer 
prevention.
Conclusion
In conclusion, our analyses enhance the understanding in etiological heterogeneity of MIBC 
by integrating molecular biology and risk factor data, showing that different molecular 
subtypes may have distinct risk profiles. Large population-based studies with detailed 
information on bladder cancer risk factors are needed to overcome the limitations of our 
study and validate our findings.
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Associations among molecular subtype schemes*.
*Based on complete data.
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